Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
AbbVie Inc (NYSE:ABBV) reports Q4 adjusted EPS of $3.31, higher than $2.92 reported a year ago and beating the consensus of $3.28.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- Overall sales increased 7.4% Y/Y (7.5% on an operational basis) to $14.89 billion, missing the consensus of $14.98 billion.
- The immunology portfolio generated $6.75 billion in sales, +13.2% (+13.3% on an operational basis). Humira sales increased 3.5% at $5.334 billion. Skyrizi sales reached $895 million, and Rinvoq jumped 84.4% to $517 million.
- Hematologic oncology portfolio sales were $1.87 billion, +4.6% (+4.7% on an operational basis). Imbruvica sales decreased 2.7% to $1.38 billion. Venclexta revenues were up 33% to $488 million.
- Sales from the neuroscience portfolio reached $1.65 billion, +19%. Aesthetics portfolio sales increased 23.3% (+22.8% on an operational basis) to $1.41 billion, with $626 million in Botox sales for cosmetic uses.
- Adjusted gross margin expanded from 81.8% to 83.6%. The adjusted operating margin also improved from 46.9% to 49.3%.
- FY22 guidance: AbbVie expects FY22 adjusted EPS of $14.00 - $14.20, versus the consensus of $13.99.
- Price Action: ABBV shares are up 0.49% at $137.67 on the last check Wednesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.